Skip to content

The efficacy and safety of telitacicept in patients with lupus nephritis:a single-center, real-world retrospective study

The efficacy and safety of telitacicept in patients with lupus nephritis:a single-center, real-world retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076828
Enrollment
Unknown
Registered
2023-10-20
Start date
2023-07-03
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus nephritis

Interventions

Sponsors

Zhangzhou Municipal Hospital of Fujian Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) All SLE patients was diagnosed according to the Systemic Lupus International Collaborating Clinics (SLICC) and American College of Rheumatology (ACR) criteria. LN is diagnosed in patients with SLE when one of the following clinical and laboratory abnormalities occurs: a, proteinuria persists > 0.5 g/24 hours, or urine protein+++ or urine protein/creatinine ratio > 500 mg/g (50 mg/mmol); b, Cell casts include red blood cell casts, hemoglobin casts, granular casts, tubular casts or mixed casts; c, Active urine sediment (excluding urinary tract infection, urine leukocytes >5/HPF, urine red blood cells >5/HPF), or red blood cell casts, or white blood cell casts. (2) Renal biopsy pathology showing immune complex-mediated glomerulonephritis further confirms the diagnosis of LN. (3) Patient's age= 18 years old (adult).

Exclusion criteria

Exclusion criteria: (1) Patients with a history of treatment with biological agents; (2) Serious organic lesions of important organs such as liver, spleen and lungs; (3) Those with primary diseases of the hematopoietic system; (4) Patients with rheumatoid arthritis, viral hepatitis and other immune system diseases; (5) Female patients during lactation or pregnancy; (6) Patients who are allergic to the drug telitacicept.

Design outcomes

Primary

MeasureTime frame
SRI-4 response rate ;

Secondary

MeasureTime frame
24h proteinuria ;The negative rate of urinary occult blood;Oral glucocorticoids reduction;Immunoglobulin;Complement;The negative rate of dsDNA;

Countries

China

Contacts

Public ContactXiao-Lu Huang

Zhangzhou Municipal Hospital of Fujian Province

443976228@qq.com+86 596 208 1126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026